Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Submitted by
admin
on September 25, 2021 - 11:00pm
Source:
Motley Fool
News Tags:
AbbVie
Regenxbio
gene therapy
wet age-related macular degeneration
Headline:
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
snippet:
AbbVie is partnering with Regenxbio to develop a gene therapy targeting eye diseases.
Regenxbio's gene therapy is already in late-stage testing.
The deal could give AbbVie a near-term growth driver and generate needed cash for Regenxbio.
Do Not Allow Advertisers to Use My Personal information
